Project Grant R61HL170457
Award Date
9/5/24
Completion Date
7/31/26
Dollars Obligated
$517K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Florida, USA
Similar Awards
This Project Grant award of $771,750 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at the University of California, Los Angeles (UCLA) to investigate the role of macrophages in regulating cardiac muscle metabolism after myocardial infarction. The key goals are to: Examine how macrophages recruited to the infarcted heart disrupt cardiac muscle metabolism and decrease NAD pools, which are critical for cardiac energetics....
This $653,854 Project Grant was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The purpose of the grant is to study the impact of cardiomyocyte-selective modulation of natriuretic peptide signaling pathways on cardiomyopathy progression and ventricular arrhythmia susceptibility in preclinical models. The specific aims are to: 1) Define how cardiomyocyte-specific modulation of PKG1 activity modifies cardiomyopathy...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to uncover the prevalence and biological roles of protein arginylation, a critical post-translational modification, in cardiovascular development and disease. The $633,720 award, effective January 25, 2025 through November 30, 2028, aims to: 1) establish a chemical proteomics platform to comprehensively profile arginylation sites in cardiac cell and...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $2,212,585 to the University of California, Los Angeles (UCLA) to investigate the role of adenine metabolism in cardiac remodeling and its potential as a therapeutic target for treating heart failure after myocardial infarction. The multi-disciplinary research team will examine the mechanisms of adenine generation, transport, and downstream effects on NAD and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $1,488,899 in funding to Young Therapeutics LLC, a pharmaceutical research and development company based in Philadelphia, Pennsylvania. The award supports the advanced development and validation of two proprietary compounds, YT-002 and YT-004, that target specific protein kinases to preserve myocardial tissue and function...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $500,089.80 to the University of Pittsburgh to investigate the role of macrophages in heart failure with preserved ejection fraction (HFPEF). The research aims to uncover the mechanisms by which inflammatory macrophages cause cardiac remodeling in HFPEF at the cellular, molecular, and functional levels. Specifically, the project will investigate how inflammatory...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $1,706,807 to the Regents of the University of Michigan from September 1, 2024 to May 31, 2028. The research aims to determine the structural mechanisms for small-molecule activation of the cardiac calcium pump (SERCA) and discover new non-cardiotoxic inhibitors of the cardiac sodium pump (NKA). These ion pumps play a critical role in cardiac function and are...
This federal Project Grant award, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research (CFDA 93.837) program, is focused on investigating the role of cardiomyocyte glutamine synthesis in cardiac physiology and heart failure. The $772,808 award, with a period of performance from December 2024 to November 2028, will be administered by Temple University. The key objectives are to: 1) examine if targeting cardiomyocyte glutamine synthesis can reduce...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $135,840 to the University of Washington from September 1, 2024 to August 31, 2026. The project will investigate the mechanisms of cardiac contractile dysfunction across multiple scales using a combined computational and experimental platform. Specifically, the work will focus on how structural perturbations to the myosin protein affect its...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $817,208 to the Broad Institute of MIT and Harvard to study the genetic basis and underlying mechanisms of heart failure. The award will leverage high-throughput functional genomic assays, including cell painting and Perturb-seq, to systematically link genetic risk loci associated with heart failure to specific molecular and cellular...